Lantheus Holdings, Inc. (NASDAQ:LNTH) Stake Lessened by Tidal Investments LLC

Tidal Investments LLC trimmed its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 32.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 11,901 shares of the medical equipment provider's stock after selling 5,720 shares during the period. Tidal Investments LLC's holdings in Lantheus were worth $1,065,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in LNTH. Janus Henderson Group PLC increased its stake in Lantheus by 72.7% during the fourth quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider's stock worth $554,583,000 after acquiring an additional 2,610,118 shares during the last quarter. Farallon Capital Management LLC increased its position in Lantheus by 79.9% during the 4th quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider's stock worth $475,590,000 after purchasing an additional 2,361,000 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its holdings in Lantheus by 40.5% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider's stock valued at $135,025,000 after buying an additional 435,445 shares during the period. Dimensional Fund Advisors LP raised its holdings in Lantheus by 2.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,347,082 shares of the medical equipment provider's stock valued at $120,510,000 after buying an additional 30,891 shares during the period. Finally, Swedbank AB lifted its position in Lantheus by 53.3% during the fourth quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider's stock valued at $99,054,000 after buying an additional 385,000 shares in the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Lantheus

In other news, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the sale, the chief financial officer now directly owns 113,860 shares in the company, valued at approximately $11,445,207.20. This represents a 8.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Mary Anne Heino sold 53,107 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the transaction, the director now directly owns 440,399 shares of the company's stock, valued at approximately $41,551,645.65. This trade represents a 10.76% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 63,109 shares of company stock worth $6,016,046 over the last quarter. 2.00% of the stock is owned by corporate insiders.

Lantheus Price Performance

Lantheus stock traded up $0.01 during midday trading on Friday, hitting $75.53. 180,885 shares of the stock were exchanged, compared to its average volume of 987,339. Lantheus Holdings, Inc. has a 1 year low of $73.11 and a 1 year high of $126.89. The firm has a market cap of $5.23 billion, a P/E ratio of 12.59 and a beta of 0.23. The company has a 50 day moving average price of $92.56 and a two-hundred day moving average price of $91.72.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). The company had revenue of $372.76 million for the quarter, compared to analyst estimates of $377.37 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The firm's quarterly revenue was up .8% compared to the same quarter last year. During the same period in the previous year, the business posted $1.69 EPS. As a group, analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently issued reports on LNTH. B. Riley dropped their price objective on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research report on Friday, March 21st. Truist Financial lowered their price target on Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a report on Thursday, May 8th. Finally, Wall Street Zen raised Lantheus from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $132.67.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.